Omnicell Inc. (OMCL) Director Sells $75,960.00 in Stock
Omnicell Inc. (NASDAQ:OMCL) Director Gary S. Petersmeyer sold 2,000 shares of the stock in a transaction that occurred on Monday, September 12th. The stock was sold at an average price of $37.98, for a total transaction of $75,960.00. Following the completion of the sale, the director now owns 17,987 shares of the company’s stock, valued at approximately $683,146.26. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Omnicell Inc. (NASDAQ:OMCL) opened at 37.95 on Monday. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of 96.32 and a beta of 0.69. The company has a 50-day moving average of $37.77 and a 200-day moving average of $32.72. Omnicell Inc. has a 1-year low of $25.06 and a 1-year high of $40.50.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, July 28th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.32 by $0.06. The firm earned $175.60 million during the quarter, compared to analysts’ expectations of $170.89 million. Omnicell had a net margin of 2.36% and a return on equity of 10.41%. The business’s revenue for the quarter was up 55.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.28 earnings per share. On average, equities analysts predict that Omnicell Inc. will post $1.58 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. boosted its position in shares of Omnicell by 77.2% in the second quarter. Victory Capital Management Inc. now owns 3,069 shares of the company’s stock worth $105,000 after buying an additional 1,337 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Omnicell by 605.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,374 shares of the company’s stock worth $150,000 after buying an additional 3,754 shares during the last quarter. PineBridge Investments L.P. raised its position in shares of Omnicell by 4.0% in the second quarter. PineBridge Investments L.P. now owns 4,555 shares of the company’s stock worth $156,000 after buying an additional 177 shares during the last quarter. Teacher Retirement System of Texas raised its position in shares of Omnicell by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 4,957 shares of the company’s stock worth $170,000 after buying an additional 600 shares during the last quarter. Finally, Stephens Inc. AR raised its position in shares of Omnicell by 20.5% in the second quarter. Stephens Inc. AR now owns 5,160 shares of the company’s stock worth $177,000 after buying an additional 878 shares during the last quarter. Hedge funds and other institutional investors own 95.26% of the company’s stock.
OMCL has been the subject of a number of research analyst reports. Sidoti downgraded shares of Omnicell from a “buy” rating to a “neutral” rating and set a $43.00 target price for the company. in a research report on Thursday, September 8th. Zacks Investment Research downgraded shares of Omnicell from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 3rd. FBR & Co increased their price target on shares of Omnicell from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Thursday, July 7th. Finally, Oppenheimer Holdings Inc. restated an “outperform” rating and set a $46.00 price target on shares of Omnicell in a research note on Tuesday, September 13th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $38.13.
Omnicell Company Profile
Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.